Form 4: Editas Medicine Director Andrew Hirsch Receives 37,500 Stock Options

Editas Medicine, Inc. Director Andrew Hirsch was granted 37,500 stock options with an exercise price of $1.91, scheduled to vest in full on June 6, 2026.

Summary

• Andrew Hirsch, a Director of Editas Medicine, Inc. (EDIT), was granted 37,500 stock options on June 6, 2025.
• The exercise price for these options is $1.91 per share.
• The options are scheduled to vest in full on June 6, 2026, and have an expiration date of June 5, 2035.
• Following this transaction, Andrew Hirsch beneficially owns 37,500 derivative securities directly.
• A Limited Power of Attorney, dated March 5, 2025, authorizes specific individuals to handle Andrew Hirsch's Section 16 reporting obligations for Editas Medicine, Inc.

Sentiment

Score: 7

Explanation: The document reports a standard equity grant to a director, which is generally a positive for aligning interests. There are no negative financial results or significant adverse events reported. The Power of Attorney is a routine administrative filing.

Positives

• The grant of stock options to Director Andrew Hirsch aligns his interests with those of shareholders, as the value of the options is tied to the company's stock performance.
• The exercise price of $1.91 provides a clear benchmark for future stock appreciation required for the options to be in-the-money.

Negatives

• The options are not immediately exercisable, with full vesting scheduled for June 6, 2026, meaning the director must remain with the company for at least a year to realize the full benefit.
• The value of the options is entirely dependent on the future stock price of Editas Medicine, Inc. exceeding the $1.91 exercise price.

Risks

• The value of the granted stock options is subject to market fluctuations and the future performance of Editas Medicine, Inc.'s stock price.
• The Power of Attorney explicitly states that the attorneys-in-fact and the company are not assuming Andrew Hirsch's responsibilities or liabilities under Section 16 of the Exchange Act, including for profit disgorgement, highlighting the individual's ongoing compliance burden.

Future Outlook

The granted stock options are scheduled to vest in full on June 6, 2026, indicating a future milestone for the director's compensation. The options have a long expiration date of June 5, 2035, providing a long-term incentive.

Management Comments

• "This option was granted on June 6, 2025 and is scheduled to vest in full on June 6, 2026."

Industry Context

Stock option grants are a common form of executive and director compensation in the biotechnology and pharmaceutical industries, particularly for companies like Editas Medicine, which are often in research and development phases and rely on long-term incentives to attract and retain talent. These grants aim to align the interests of directors with the long-term success and stock performance of the company.

Comparison to Industry Standards

• The grant of stock options to a director is a standard practice in corporate governance, especially in growth-oriented sectors like biotechnology.
• The specific number of options (37,500) and the exercise price ($1.91) would typically be evaluated against peer companies' director compensation packages, considering company size, stage of development, and market capitalization. Without specific peer data, a direct comparison is not possible from this document alone.
• The vesting schedule (one year for full vesting) is a common structure for director equity grants, designed to encourage continued service and alignment.

Corporate Governance

Related Party Transactions

• The grant of stock options to Andrew Hirsch, a director, constitutes a transaction with a related party. This is a standard form of compensation and is disclosed as required by SEC regulations.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with shareholder value creation, as the options gain value only if the stock price increases. It represents a form of non-cash compensation that dilutes existing shares if exercised, but this is a common practice.

Next Steps

• The stock options are scheduled to vest in full on June 6, 2026.
• Andrew Hirsch will be able to exercise the options after vesting and before the expiration date of June 5, 2035.

Key Dates

Keywords

Editas Medicine, EDIT, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Biotechnology, Gene Editing, Andrew Hirsch